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Introduction
In 1868, Guilaume Duchenne, a French physician living in Paris defined a 
pseudohypertrophic paralysis showing a muscular appearance in the extremities 
(1-3). Duchenne muscular dystrophy is an X-linked form of muscular dystrophy 
involving cardiac and skeletal muscles (4-6). The prevalence is 1/3500 in boys, but 
it may involve females with Turner’s syndrome too (XO) (1,4,5). The responsible 
gene was identified in 1987. It is located on the short arm of the X chromosome 
and it codes for the protein dystrophin which is responsible for the stability of the 
cellular basement membrane (4,5,7). Muscular fibers without dystrophin are very 
sensitive to mechanical contraction. This defect is the cause of muscle fiber death 
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Abstract
Objective
Duchenne muscular dystrophy (DMD) is a degenerative disease that usually 
becomes clinically detectable in childhood as progressive proximal weakness. 
No cure is yet available for DMD, but the use of steroids improves muscle 
strength and function. This study has been carried out to select the best steroid 
for the management of DMD.
Materials & Methods
This study is a single-blind, randomized clinical trial with a sample volume of 
34 DMD patients. Half of these patients were treated with deflazacort (0.9 mg/
kg daily) and the other half with prednisone (0.75 mg/kg daily) for a period of 
18 months. The motor function score and excess body weight were registered 
one year after the start and also at the end of the study and compared between 
the two groups.
Results
Deflazacort was more effective in the improvement of motor function after one 
year, but there was no significant difference between the two drugs at the end 
of the study (18 months after start). Weight gain after one year and at the end of 
the study was higher in prednisone group and steroid treatment with deflazacort 
appears to cause fewer side effects than prednisone regarding weight gain.
Conclusion
Deflazacort seems to be more effective than prednisone in the improvement 
of motor function causing fewer side effects, particularly weight gain. This 
medication may be important for the improvement of motor function and could 
be used as the best steroidal treatment for Duchenne muscular dystrophy.
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finally leading to replacement by fibrous connective 
tissue (4,5,7). 
Duchenne dystrophy patients suffer from a progressive 
predictable muscular weakening. Most of the patients 
lose their ability to move when they are 6 to 12 years old 
(1,4,5). Cardio-respiratory failure and scoliosis occur 
gradually (4,5).
Many treatment plans such as basic cell and myoblast 
transfer, replacement or repair of the problematic cell 
and drug therapy are under research (1,6,8,9). Steroids 
have shown advantages in retaining muscular function, 
such as increasing the muscular bulk and diminishing 
the muscular degeneration speed, but are associated with 
severe alternative complications (4,7). Prednisone was 
first used, then a newer steroid called deflazacort which 
is an oxalone extract of prednisone was experimented 
and the numerous studies showed that this medicine 
is as competent as prednisone in retaining muscular 
function with fewer complications (4,6,10-12). The 
objective of this study was to compare the advantages 
and disadvantages of deflazacort and prednisone in the 
treatment of Duchenne muscular dystrophy. The results 
of this study may be used to select a more appropriate 
and more effective treatment method. 
Materials & Methods
In this study, all patients with the 5 below diagnostic 
criteria for Duchenne dystrophy were enrolled:
-Muscular weakness below the age of 5 years
-Male gender
-Proximal muscle weakness
-An increase of more than 40 fold the normal limit of CK 
in the beginning of the symptoms
-Confirmation of the diagnosis by:
a) Muscle biopsy to prove dystrophin deficiency or
b) Genetic evaluation to confirm dystrophin gene deletion
After enrollment, according to the above criteria, 
the patients were randomly placed on one of the 
following mentioned protocols; 0.75 mg/kg/single 
dose/day prednisone as 50 mg tablets and in case any 
complications occurred this dose was decreased to 0.3 
mg/kg and if there still were complications, the drug 
was discontinued and the patient was excluded from the 
study; 0.9 mg/kg/single dose/day deflazacort and in case 
any complications occurred this dose was decreased to 
0.5 mg/kg and if the complications were uncontrollable 
with this dose the patient was excluded from the study. 
The patients were examined at the beginning and also in 
between the study as mentioned below for the following 
mentioned functions:
Every 3 months for movement function using the below 
modalities and grading in three levels for each modality, 
in which increase in each modality demonstrates 
worsening of the muscular function. These modalities 
were:
A. Going up four 17 cm stairs 
B. Getting up from the sitting position to the standing 
     position 
C. Walking 10 meters on flat ground 
Grading:
Grade 1: Accomplishing the task without assistance
Grade 2: Accomplishing the task with assistance
Grade 3: Not being able to accomplish the task
It is necessary to mention the fact that movement ability 
was evaluated in every visit.
•	 Measurement of height and comparing it with the 
height at the beginning of the study every 3 months 
according to the children’s standard height growth 
chart. Considered abnormal in case of no increase 
based on the height percentile at the beginning of 
the study. 
•	 Measurement of weight every 3 months. 
•	 Measurement of blood pressure every 3 months and 
comparing it with the standard blood pressure chart 
for children. 
•	 Annual ophthalmic evaluation for cataract. 
•	 Annual orthopedic evaluation for scoliosis and in 
case of a higher than 20 degree increase, sending the 
patient for repairment surgery. 
•	 Checking for glucosuria every 3 months. 
•	 Recommendations to prevent weight gain in every 
visit for a 3-month-period and introducing the 
patient to a nutrition specialist in case of 5% to 10% 
increase in weight. 
•	 Annual spirometry and vital lung capacity as an 
index for respiratory function by a child respiratory 
subspecialist. A vital lung capacity of less than 80% 
normal based on the patient’s age and gender was 
considered as abnormal (13). 
•	 Annual referral to a child cardiac subspecialist for 
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have no intention other than to empty people’s pockets. 
Of these eight cases who did not continue therapy, three 
were on deflazacort and five on prednisone medication. 
This study was continued with 26 cases, of which 14 
were patients using deflazacort and 12 were patients 
using prednisone. These patients were followed up for 18 
months till March 21, 2009 and in every visit everything 
was carried out according to the study method.
The mean age of the patients in the deflazacort group 
was 7.1±1.98 years (range, 3.2-10.5) and for patients 
on prednisone medication this figure was 7.37±1.27 
years (range, 6-10). In this study, after one year and also 
after 18 months the mean of motor function index and 
the mean weight was calculated and recorded for each 
patient and the two groups were compared regarding 
these factors at that time. We have to mention that the 
motor function index has a 9 grade score based on the 
ability to get up from the ground, walking on flat ground 
for 10 meters and going up four steps with the height 
of 17 cm each. Based on the method mentioned before, 
score 1 indicates the ability to work without assistance, 
score 3 indicates inability to perform. Therefore, 9 is 
the worst and 3 is the best motor function index. The 
increase or decrease in this index compared with the 
beginning of the study which demonstrates worsening or 
improvement of the movement function was calculated 
for each patient for both follow-ups separately and the 
mean of these percentages were compared between the 
two groups.
One year after the study started, the mean of this 
percentage for deflazacort group was 14.99% ±11.19% 
(range, 0%-40%) compared with the beginning of 
treatment showing improvement in motor function 
in this group (as a result of decrease in the motor 
function index). The mean percentage of this index 
for the prednisone group at this time compared with 
the beginning of therapy was 18.07%±5.2% (range, 
20%-25%).
With the use of paired t-test, comparison of these two 
showed that there is a significant difference between 
them (p=0.001) and deflazacort has a better role in motor 
function than prednisone (Table 3).
After one year from the beginning of the study, the 
percentage of weight increase compared with the 
weight before therapy in the deflazacort group was 
measurement of ejection fraction as an index for 
cardiac function. An ejection fraction less than 55% 
normal based on the patient’s age and gender was 
considered abnormal. 
For the patients enrolled into the study, 500 mg calcium 
and 400 IU vitamin D was prescribed in addition to 
steroid. 
Statistical Analysis
SPSS 17 for Windows (SPSS Inc., Chicago, Illinois) was 
used for statistical analysis. Comparison between groups 
for quantitative variables was carried out by the T-test 
or nonparametric equivalent test and for qualitative 
variables the Chi-square test was used. This study was 
confirmed by the ethical committee of Shahid Beheshti 
University of Medical Sciences and written consent was 
obtained from the parents of children who were enrolled 
into the study. 
Results
This study was performed to compare the effect of 
deflazacort and prednisone in the treatment of Duchenne 
muscular dystrophy. Thirty-four Duchenne muscular 
dystrophy patients based on the inclusion criteria were 
enrolled into the study from 23rd of September 2008 to 21st 
of March 2009. The patients were treated alternatively 
by prednisone or deflazacort; prednisone was prescribed 
for 17 patients and deflazacort was prescribed for 17 
patients with the dose mentioned previously. 
Eight of the patients were excluded from the study for 
different reasons. The advantages and probable side 
effects of the medications were explained completely for 
the children’s parents together with Duchenne muscular 
dystrophy, the treatments available and the outcome of 
this disabling disease. Nevertheless, some of the parents 
changed their minds, maybe because of the threat of 
steroid treatment and the side effects that are mentioned 
by some people and also some physicians. Another cause 
for the parents’ give-up after a few weeks that happened 
for four of the children was the immediate response to 
treatment the parents expected despite the complete 
given explanation regarding this matter, which may be 
due to the false broadcasting by media or sites on the 
internet introducing medications that promise complete 
cure for this disease. These have no scientific base and 
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and 32.04%±8.88% (range, 17.5%-45%), respectively, 
expressing no significant difference statistically between 
the two groups (p=0.046) and a higher increase in weight 
using prednisone (Table 3).
In this study, the patients’  blood pressure and height 
was measured every 3 months revealing no increase in 
blood pressure in any of the groups according to the age-
specific standard curve.
In the deflazacort group, the patients’ mean height was 
116.6±11.65 cm between the 25% to 50% percentile 
according to age, which was 122.06±9.05 cm for the 
prednisone group. This index was 123.39±12.20 and 
128.31±8.8 for deflazacort and prednisone, respectively 
at the end of the study for the same percentiles presenting 
an appropriate growth in height in both groups. Of 
course, in order to compare the drug effects on blood 
pressure and height growth a more prolonged study is 
necessary.
Other evaluations regarding this study that have been 
carried out annually were the evaluation of the vital 
respiratory capacity, of which a less than 80% normal 
based on age and gender was considered abnormal 
(13) showing a decrease in the respiratory function, in 
which none of the groups had an abnormal vital capacity 
throughout the study.
In addition, no cardiomyopathy was observed in the 
patients based on the decrease in ejection fraction (the 
normal EF was considered as 55% above normal in 
echocardiography. This index was always measured by a 
confirmed pediatric cardiology subspecialist). There was 
also no cataract observed in the annual follow-up.
In the spinal column evaluation, there was no scoliosis. 
Apart from one patient in the deflazacort group who had 
a 10 percent scoliosis in the beginning of the study and 
was introduced to an orthopedic specialist for a brace 
and had no increase in scoliosis in the follow-up, there 
was no other scoliosis detected.
There was no positive urinalysis for glucosuria in any of 
the groups in the 3-month evaluation.
Complications such as cardiomyopathy, decrease in 
respiratory function and scoliosis are usually seen in 
Duchenne muscular dystrophy when the patient reaches 
a higher age and is unable to move and the patients in this 
study have a mean age of 7, too soon for these problems.
All the patients were able to walk and none needed a 
12.95%±9.24% (range, 2.08%-29.41%). This figure was 
21.65%±6.68% (range, 10%-30%) for the prednisone 
group (Table 3).
There was a significant difference between the mean 
weight before therapy and one year after therapy between 
these two groups (p=0.001) and this points to a higher 
increase in weight in the prednisone group. We have to 
mention that all the patients under prednisone treatment 
and some of the patients under deflazacort treatment had a 
5% increase in weight and were subsequently introduced 
to the nutrition consultant for weight control and were 
subsequently given advice. Therefore, in the prednisone 
group the dose of prednisone was decreased from 0.75 
mg/kg to 0.3 mg/kg for all the patients throughout a one-
year process, but in the deflazacort group the decrease 
was from 0.9 mg/kg to 0.6 mg/kg in only three patients.
One year after the study started, four patients from the 
prednisone group were excluded from the study as a 
result of uncontrollable weight increase despite nutrition 
consultation. These four patients also had motor function 
reduction and the parents did not accept change to 
deflazacort and continuation of the therapy.
Therefore, the last 6 months of the study was continued 
with 14 patients in the deflazacort group and eight 
patients in the prednisone group.
After the study was finished (18 months after the 
beginning of the study), the mean of motor function 
index compared with the beginning of the study was 
24.46%±4.52% (range, 40%-60%) for the deflazacort 
group and 29.24%±14.79% (range, 20%-60%) showing 
improvement in motor function in deflazacort group 
patients (Table 3). According to the paired t test no 
significant difference was detected between these two 
groups (p=0.128) demonstrating the fact that none 
of these medications have advantages over the other. 
Maybe the reason for better results for deflazacort was 
because after one year four patients from the prednisone 
group were excluded from the study as a result of 
uncontrollable weight gain and these were the patients 
who had worsening of motor function compared with 
the beginning of the study and the eight patients who 
continued the study had a better motor function state.
At this time, the mean weight gain compared with the start 
of this study in the deflazacort group and the prednisone 
group was 21.67%±11.96% (range, 4.17%±44.12%) 
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therapy stayed in the study causing the disappearance 
of statistical difference between the two groups after 18 
months. If the patients were not excluded from the study, 
deflazacort would still be the permanent medication.
Regarding weight gain, one of the side effects of these 
medications, a significant difference between these two 
drugs after one year (p=0.001) and after completion of 
the study (p=0.046) was observed demonstrating that 
deflazacort causes less weight gain in contrast with 
prednisone.
About other side effects of these drugs, no decrease in 
height, increase in blood pressure, scoliosis, cataract, 
glucosuria, cardiomyopathy and motor function 
reduction was detected in the two groups; in explanation 
of this matter, we have to emphasize the low mean age 
of the patients regarding cardiomyopathy, scoliosis and 
reduction in motor function, which was 7 years; as in 
Duchenne muscular dystrophy, these complications are 
caused at higher ages. When the patients are bedridden, 
cardio-respiratory failure is the main cause of death 
and regarding height growth, diabetes, cataract and 
increase of blood pressure, more prolonged studies are 
necessary and mentioning a definite opinion about these 
complications is not possible.
In a study conducted by Marco D Banifati in Italy in 
2000 (11), the impact of these medications was evaluated 
in a randomized double-blind study on a less number of 
patients in contrast with this study, in which 18 patients 
were enrolled in the study. The results showed the equal 
impact of the drugs on motor function and also the less 
influence of deflazacort on weight gain in contrast with 
prednisone. This indicates the same result as our study, 
apart the fact that we had a larger sample size pointing to 
a more valid statistical calculation.
In another study, carried out by Bernd Reitter in Germany 
in 1995 (12), the impact of these drugs were evaluated 
on 67 patients who had lost their movement ability. In 
physical examination, the muscle strength of twenty 
separate muscles was evaluated according to a 10 degree 
score 3 to 15 months after medication. These muscles 
were compared between the two groups. The dose of 
medications was exactly the same as our study. Finally, 
an equal influence was detected on the motor function 
between these two drugs. In addition deflazacort had less 
Impact on weight gain, similar to our study. 
wheelchair. Although none of the two groups had such 
difficulties, comparison between these two groups 
regarding the side effects needs a prolonged study that 
will be followed up in these patients.
In order to find out whether there is any correlation 
between the weight gain after medication and motor 
function reduction, Pearson test (r=0.665) was used 
and one-year after medication there was a significant 
correlation between the two indices (p<0.001) which 
shows that the possible reason why deflazacort was better 
than prednisone in the improvement of motor function 
after one year was less weight gain in the deflazacort 
group. Maybe it would be feasible to control weight 
gain when the patient is under prednisone therapy by 
following nutritional advice; therefore, these two drugs 
may have similar impact leading to prescription of 
prednisone instead of deflazacort in patients who can not 
use deflazacort, as deflazacort is a more expensive, less 
available medication. 
Discussion
The therapeutic effects of corticosteroids in preventing 
the progress of muscular dystrophy have been evaluated 
in many studies around the world. As no definite therapy 
has been found for this disease, corticosteroid treatment 
has been mentioned in textbooks of pediatric neurology 
for Duchenne dystrophy (4,5).
At the time being, two types of steroids have been 
suggested for this disease; namely, the common and 
routine type of prednisone and another type which is an 
oxazoline derivative of prednisone, called deflazacort. 
The main and basic question is “Which drug has better 
therapeutic effects?”
In this study, after one year of therapy, deflazacort 
was better than prednisone regarding motor function 
improvement (p=0.001), but at the end of the study (18 
months after the beginning), there was no significant 
difference between these two medications in motor 
function improvement showing an equal effect of these 
drugs (p=0.128). This may be the result of excluding four 
patients from the prednisone group due to uncontrollable 
weight gain after the first year of the study. These 
were patients with severe reduction of motor function 
regardless of prednisone therapy. Those patients with 
a better situation in motor function under prednisone 
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getting bedridden in patients on deflazacort medication. 
Deflazacort is also efficient in the improvement of 
cardio-respiratory function consequently leading to 
development in the quality of life. Weight gain was a 
complication mentioned for this drug just like our study 
and the fact that this problem may be controlled by 
precise nutritional advice was also referred to.
In Biggar et al’s study carried out in Canada and Italy 
(5), the excluded cases were those who worried about 
steroid consumption. This situation is pointed out by 
some physicians. In order to avoid such situations, the 
fact that the advantages of steroid prescription over 
the probable disadvantages in correct and indicated 
circumstances should be expressed in public health 
education. Deflazacort in comparison with prednisone 
is an expensive drug and this is the most important 
limitation in our study.
In conclusion, deflazacort is the best steroid for 
treatment of Duchenne muscular dystrophy with a 
better influence on the improvement of motor function 
compared with prednisone. In studies which demonstrate 
an equal effect of deflazacort and prednisone on motor 
function improvement, the former medication shows 
fewer side effects. On this account, as our study showed, 
if the patient’s weight could be controlled when on 
prednisone medication, maybe prednisone could be 
prescribed instead of deflazacort when deflazacort 
prescription is not possible such as circumstances the 
patient can not afford to use deflazacort.
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In another study, by WD Biggar in Italy and Canada in 
2004 (5), two different deflazacort treatment protocols 
were assessed for Duchenne muscular dystrophy. One 
group used 0.6 mg/kg/day deflazacort for the 20 first days 
of the month and the other group used 0.9 mg/kg/day 
deflazacort everyday. Both groups had a separate control 
group using no medication. In this study, movement 
ability was better in the control group who was under 
no medication. The control group for the group under 
0.9 mg/kg/day deflazacort everyday-which was the dose 
used in our study and most other studies, indicating the 
most efficient dose-had more significant motor ability. 
The interesting point in this study was the lower weight 
of patients under deflazacort therapy. Improvement 
in movement leading to physical activity; therefore, 
preventing weight gain in the treated patients was the 
reason for the lower weight. In our study, a similar result 
was detected; weight gain has direct influence on motor 
function reduction and if the patients using steroids 
control their weight based on nutritional advice, the 
influence of these medications, especially prednisone, 
on improvement of motor function is more significant. 
Maybe in our study, the Iranian diet with a higher fat 
content and also the higher parent affection in Iranians-
paying more attention to the child-was the reason for 
weight gain in the deflazacort group.
In WD Biggar’s study in 2000 (14), the impact of 
deflazacort was assessed on thirty 7 to 15-year-old 
Duchenne muscular dystrophy patients. The control 
group consisted of twenty-four patients under no therapy. 
In order to evaluate motor function, similar criteria to our 
study were used. The results emphasized the influence 
of deflazacort on maintenance of motor function in 
Duchenne muscular dystrophy. No glucosuria, blood 
pressure rise and uncontrollable infection were detected. 
Sylvie Houde et al’s study in 2007 in Canada evaluating 
the impact of deflazacort on Duchenne muscular 
dystrophy (12) had a more prolonged follow-up than our 
study, which took eight years. This was a retrospective 
study on 79 patients. The treated group consisted of 
37 patients and the non-treated group composed of 42 
patients. The dose of medication prescribed was exactly 
similar to our study. In this study, the results showed 
the better influence of deflazacort in comparison to the 
group under no medication showing a two-year delay in 
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Table 1. The Mean Age of Patients in the Two Groups
 Prednisone Deflazacort
Mean Age (year) 7.37±1.27 7.1±1.98
 
Table 2. Mean of Motor Function Index and Weight in the Two Groups
Variables Group Before Treatment After 1 year After 1.5 years
Mean ± SD (95% CI for mean) of Motor 
Function Index
P 5.0±0.53 (4.6-5.5) 5.25±1.03 (4.4-6.1) 5.75±1.67 (4.4-7.2)
D 4.93±0.99 (4.4-5.5) 4.36±1.15 (3.7-5.0) 4.64±1.44 (3.8-5.5)
Mean ± SD (95% CI for mean) of Weight 
(Kg)
P 23.31±3.95 (20.0-26.6) 28.37±5.04 (24.2-32.6) 30.81±5.68 (26.1-35.6)
D 20.39±4.63 (17.7-23.1) 23.03±5.51 (19.8-26.2) 24.71±5.67 (21.4-28.0)
  
Table 3. Mean of Change in the Motor Function Index and Weight and Comparison Between the Two Groups
Variables Group After 1 year After 1.5 years
Mean ± SD (95% CI for mean) of 
Change of Motor Function Index (%)
P ↑5.20±18.07 (-9.9 – 20.3) ↑14.79±29.24 (-9.7 – 39.2)
D ↓11.19±14.99 (-19.8 – -2.5) ↓4.52±26.46 (-19.8 – 10.7)
Paired T- Test 
(P- value) 0.001 0.128
Mean ± SD (95% CI for mean) of 
Change of Weight (%)
P ↑21.65±6.68 (16.1 – 27.2) ↑32.04±8.88 (24.6 – 39.5)
D ↑12.95±9.23 (7.6 – 18.3) ↑21.67±11.96 (14.8 – 28.6)
Paired T-Test 
(P-value) 0.001 0.046
P value less than 0.05 as significant.
↑=increase, ↓=decrease
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